A groundbreaking study has been conducted to assess the potential of a rapid, low-cost blood test that can detect multiple types of cancer. The test, known as the Dxcover® Cancer Liquid Biopsy, utilizes Fourier transform infrared (FTIR) spectroscopy combined with machine-learning algorithms. The study involved 2092 patients and examined eight different cancers. The results showed promising area under the receiver operating characteristic curve (ROC) values for various cancer types, such as brain (0.90), breast (0.76), colorectal (0.91), and others. The test can detect early-stage disease and can be adjusted to maximize either sensitivity or specificity based on different healthcare system requirements.
The study emphasizes the importance of early cancer diagnosis, as treatment is more effective and potentially less toxic at earlier stages. The spectroscopic blood test offers a comprehensive analysis of tumor and immune-derived markers in blood, making it a potential game-changer in cancer diagnostics.